Medical Management of Meningiomas

Mohammed A Azab; Kyril Cole; Emma Earl; Chris Cutler; Joe Mendez; Michael Karsy

doi:10.1016/j.nec.2023.02.002

Medical Management of Meningiomas

Neurosurg Clin N Am. 2023 Jul;34(3):319-333. doi: 10.1016/j.nec.2023.02.002. Epub 2023 Apr 12.

Authors

Mohammed A Azab¹, Kyril Cole², Emma Earl², Chris Cutler³, Joe Mendez⁴, Michael Karsy⁵

Affiliations

¹ Biomolecular Sciences Graduate Program, Boise State University, 1910 University Drive, Boise, ID 83725, USA.
² School of Medicine, University of Utah, 30 North 1900 East, Salt Lake City, UT 84132, USA.
³ Chicago Medical School, Rosalind Franklin University of Medicine and Science, 3333 N Green Bay Rd., North Chicago, IL 60064, USA.
⁴ Department of Neurosurgery, Huntsman Cancer Institute, University of Utah, 2000 Circle of Hope Dr., Salt Lake City, UT 84112, USA.
⁵ Department of Neurosurgery, Clinical Neurosciences Center, University of Utah, 175 North Medical Drive East, Salt Lake City, UT 84132, USA. Electronic address: neuropub@hsc.utah.edu.

PMID: 37210123
DOI: 10.1016/j.nec.2023.02.002

Abstract

Meningiomas represent the most common type of benign tumor of the extra-axial compartment. Although most meningiomas are benign World Health Organization (WHO) grade 1 lesions, the increasingly prevalent of WHO grade 2 lesion and occasional grade 3 lesions show worsened recurrence rates and morbidity. Multiple medical treatments have been evaluated but show limited efficacy. We review the status of medical management in meningiomas, highlighting successes and failures of various treatment options. We also explore newer studies evaluating the use of immunotherapy in management.

Keywords: Chemotherapy; Immunotherapy; Medical management; Meningioma; Radiosurgery.

Publication types

Review

MeSH terms

Humans
Meningeal Neoplasms* / surgery
Meningioma* / surgery
Radiosurgery*
Retrospective Studies
Treatment Outcome